Een studie van mezagitamab bij volwassenen met primaire IgA nefropathie nieraandoening
Een fase 3 multicenter, gerandomiseerde, dubbelblinde, placebo-gecontroleerde studie om de werkzaamheid en veiligheid van Mezagitamab (TAK-079) te evalueren bij deelnemers aan de studie met primaire IGA-nefropathie in combinatie met stabiele achtergrondtherapie
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo.
Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed by chance in either the mezagitamab or placebo treatment group at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. Participants can be in the study for 2 years (104 weeks). Participants will receive study treatment for about half a year (22 weeks) and then be observed for the remainder of the study (about 1.5 years). During observation, participants will continue to have check-ups about every month.
In the open-label group, a small number of participants who either have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab.
During the study, participants will visit their study clinic several times.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Takeda Contact
- Telefoonnummer: +1-877-825-3327
- E-mail: medinfoUS@takeda.com
Studie Locaties
-
-
-
Ciudad Autonoma Buenos Aires, Argentinië, 1280
- Werving
- Hospital Britanico de Buenos Aires
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Hernan Trimarchi Jurado
-
Córdoba, Argentinië, X5016
- Werving
- Clinica Privada Velez Sarsfield
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Rafael Alberto Maldonado
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentinië, C1425AGC
- Werving
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Alejandra Smuclir Quevedo
-
-
La Plata
-
Buenos Aires, La Plata, Argentinië, 1902
- Werving
- Framingham Centro Medico
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Martin Mamberti
-
-
-
-
New South Wales
-
Liverpool, New South Wales, Australië
- Werving
- South Western Sydney Local Health District - University of New South Wales - Liverpool Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Beata Zahorowska
-
-
Queensland
-
Milton, Queensland, Australië
- Werving
- Core Research Group
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- David Colquhoun
-
-
Victoria
-
Box Hill, Victoria, Australië, 3128
- Werving
- Eastern Health
-
Hoofdonderzoeker:
- Darren Lee
-
Contact:
- Site Contact
-
Clayton, Victoria, Australië
- Werving
- Monash Heath - Monash University - Monash Medical Centre
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Jessica Ryan
-
St Albans, Victoria, Australië, 3021
- Werving
- Western Health Sunshine Hospital
-
Hoofdonderzoeker:
- Eugenia Pedagogos
-
Contact:
- Site Contact
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2R 0X7
- Werving
- Sheldon M. Chumir Health Centre
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Louis Girard
-
-
Ontario
-
London, Ontario, Canada, N6A5A5
- Werving
- London Health Sciences Centre
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Matthew Weir
-
Toronto, Ontario, Canada, M4G 3E8
- Werving
- Sunnybrook Health Sciences Centre
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Michelle Hladunewich
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Werving
- Peking University First Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Jicheng Lv
-
Changping, Beijing Municipality, China, 102218
- Werving
- Beijing Tsinghua Changgung Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Yuehong Li
-
-
Fujian
-
Xiamen, Fujian, China, 361004
- Werving
- Zhongshan Hospital Xiamen University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Bo Xu
-
-
Guangdong
-
Guangdong, Guangdong, China, Guangdong
- Werving
- The First Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Wei Chen
-
Guangzhou, Guangdong, China, 510080
- Werving
- Guangdong General Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Zhiming Ye
-
Shenzhen, Guangdong, China, 518000
- Werving
- Peking University Shenzhen Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Zu-Ying Xiong
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Werving
- The Third Xiangya Hospital of Central South University Yuelu District
-
Hoofdonderzoeker:
- Hao Zhang
-
Contact:
- Site Contact
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, China, 14010
- Werving
- The First Affiliated Hospital of Baotou Medical College
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Zengyan Li
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Werving
- Zhongda Hospital Southeast University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Liu Bicheng
-
Nantong, Jiangsu, China, 226001
- Werving
- Affiliated Hospital of Nantong University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Xinzhong Huang
-
Wuxi, Jiangsu, China, 214023
- Werving
- Wuxi People's Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Liang Wang
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Werving
- The First Affiliated Hospital of Nanchang University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Yan Yan
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Werving
- Shandong University - Qilu Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Xiang-Dong Yang
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200000
- Werving
- Shanghai Jiao Tong University School of Medicine (SJTUSM) - Renji Hospital - Eastern Branch
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Leyi Gu
-
Shanghai, Shanghai Municipality, China, 200025
- Werving
- Ruijin Hospital of Shanghai Jiaotong University School of Medicine
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Jingyuan Xie
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Werving
- West China Hospital Sichuan University
-
Hoofdonderzoeker:
- Ping Fu
-
Contact:
- Site Contact
-
Chengdu, Sichuan, China, 610072
- Werving
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Guisen Li
-
Yibin, Sichuan, China, 644099
- Werving
- The Second People's Hospital of Yibin
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Deqiong Xie
-
-
Xiangzhou District, Guangdong Province
-
Zhuhai, Xiangzhou District, Guangdong Province, China, 519000
- Werving
- Fifth Affiliated Hospital Sun Yat-Sen University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Cheng Wang
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Werving
- The Second Affiliated Hospital, Zhejiang University, School of Medicine
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Kunling Ma
-
Ningbo, Zhejiang, China, 315010
- Werving
- The First Affiliated Hospital of Ningbo University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Xueyan Bian
-
-
-
-
-
Mainz, Duitsland, 55131
- Werving
- Universitaetsmedizin der Johannes - Gutenberg Universitaet Mainz
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Julia Weinmann-Manke
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, Duitsland, 52074
- Werving
- Uniklinik RWTH Aachen
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Claudia Seikrit
-
-
Thuringia
-
Jena, Thuringia, Duitsland, 7747
- Werving
- Universitaetsklinikum Jena
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Martin Busch
-
-
-
-
-
Bordeaux, Frankrijk, 33076
- Werving
- CHU Bordeaux, CHU Pellegrin
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Claire Rigothier
-
Limoges, Frankrijk, 87042
- Werving
- CHU Limoges Service de Nephrology
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Fatouma Toure
-
Montpellier, Frankrijk, 34090
- Werving
- Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Lapeyronie
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Moglie Le Quintrec
-
Nantes, Frankrijk, 44093
- Werving
- CHU de Nantes
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Simon Ville
-
Paris, Frankrijk, 75020
- Werving
- Hospital Tenon
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Khalil Karoui
-
-
Paris
-
Créteil, Paris, Frankrijk, 94000
- Werving
- Hospital Henri Mondor
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Vincent Audard
-
-
-
-
-
Budapest, Hongarije, 1083
- Werving
- Semmelweis Egyetem - Belgyogyaszati es Onkologiai Klinika (I.sz. Belgyogyaszati Klinika)
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Akos Petho
-
-
-
-
Hong Kong Island
-
Hong Kong, Hong Kong Island, Hongkong
- Werving
- The University of Hong Kong - Department of Medicine
-
Hoofdonderzoeker:
- Sydney Chi Wai Tang
-
Contact:
- Site Contact
-
-
-
-
-
Bologna, Italië, 40138
- Werving
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Gaetano La Manna
-
Brescia, Italië, 25124
- Werving
- ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Federica Mescia
-
Genoa, Italië, 16132
- Werving
- IRCCS Ospedale Policlinico San Martino
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Francesca Viazzi
-
Messina, Italië, 98122
- Werving
- Az Ospedaliera Universitaria Policlinico G Martino
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Domenico Santoro
-
Milan, Italië, 20100
- Werving
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Giuseppe Castellano
-
Pavia, Italië, 27100
- Werving
- Istituto Maugeri IRCCS Pavia
-
Hoofdonderzoeker:
- Ciro Esposito
-
Contact:
- Site Contact
-
Piacenza, Italië, 29121
- Werving
- Azienda Unita Sanitaria Locale Piacenza (AUSL) Ospedale "Guglielmo da Saliceto
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Roberto Scarpioni
-
Torino, Italië, 10126
- Werving
- AOU Citta della Salute e della Scienza di Torino
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Luigi Biancone
-
-
-
-
Aichi-ken
-
Kasugai-Shi, Aichi-ken, Japan, 486-8510
- Werving
- Kasugai Municipal Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Yosuke Saka
-
Nagoya, Aichi-ken, Japan, 466-8650
- Werving
- Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Shoji Saito
-
Toyoake-shi, Aichi-ken, Japan, 470-1192
- Werving
- Fujita Health University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Naotake Tsuboi
-
-
Chiba
-
Chiba, Chiba, Japan, 260-8712
- Werving
- National Hospital Organization Chiba Medical Center Chibahigashi National Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Takehiko Kawaguchi
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japan, 812-8582
- Werving
- Kyushu University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Toshiaki Nakano
-
-
Fukushima
-
Fukushima, Fukushima, Japan, 960-1295
- Werving
- Fukushima Medical University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Kazama Junichiro
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japan, 734-8551
- Werving
- Hiroshima University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Takao Masaki
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8648
- Werving
- Hokkaido University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Daigo Nakazawa
-
-
Kanagawa
-
Kamakura-shi, Kanagawa, Japan, 247-8533
- Werving
- Shonan Kamakura General Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Hidaka Sumi
-
Kawasaki-shi, Kanagawa, Japan, 213-8587
- Werving
- Toranomon Hospital Kajigaya
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Naoki Sawa
-
Yokohama, Kanagawa, Japan, 236-0004
- Werving
- Yokohama City University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Kouichi Tamura
-
-
Miyagi
-
Sendai, Miyagi, Japan, 981-3281
- Werving
- Japan Community Health care Organization Sendai Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Santoru Sanada
-
-
Nara
-
Kashihara-shi, Nara, Japan, 634-8522
- Werving
- Nara Medical University Hospital
-
Hoofdonderzoeker:
- Kazuhiko Tsuruya
-
Contact:
- Site Contact
-
Nara, Nara, Japan, 630-8581
- Werving
- Nara Prefecture General Medical Center
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Hideo Tsushima
-
-
Oita Prefecture
-
Yufu-shi, Oita Prefecture, Japan, 879-5593
- Werving
- Oita University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Fukuda Akihiro
-
-
Osaka
-
Osaka, Osaka, Japan, 530-8480
- Werving
- Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofuka
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Takeshi Matsubara
-
-
Saitama
-
Koshigaya-shi, Saitama, Japan, 343-8555
- Werving
- Dokkyo Medical University Saitama Medical Center
-
Hoofdonderzoeker:
- Tetsuro Takeda
-
Contact:
- Site Contact
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8431
- Werving
- Juntendo University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Yusuke Suzuki
-
Shinjuku-Ku, Tokyo, Japan, 160-0023
- Werving
- Tokyo Medical University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Takahito Moriyama
-
-
Yamanashi
-
Chuo-shi, Yamanashi, Japan, 409-3898
- Werving
- University of Yamanashi Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Ayumu Nakashima
-
-
-
-
-
Kuala Lumpur, Maleisië, 50603
- Werving
- Universiti Malaya Medical Centre (UMMC)
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Soo Kun Lim
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Maleisië, 56000
- Werving
- Universiti Kebangsaan Malaysia (UKM) - Medical Centre (Pusat Perubatan) (Hospital Canselor Tuanku Muhriz (HCTM))
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Lydia Kamaruzaman
-
-
Pahang
-
Kuantan, Pahang, Maleisië, 25100
- Werving
- Hospital Tengku Ampuan Afzan
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Fariz Safhan Mohamad Nor
-
-
Perak
-
Taiping, Perak, Maleisië, 34000
- Werving
- Hospital Taiping
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Kok Seng Teng
-
-
Selangor
-
Kajang, Selangor, Maleisië, 43000
- Werving
- Hospital Sultan Idris Shah Serdang (Hospital Serdang)
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Li Lian Tay
-
Subang Jaya, Selangor, Maleisië, 47500
- Werving
- Sunway Medical Centre (SMC)
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Rosnawati Yahya
-
-
-
-
-
Leiden, Nederland, 2333 ZA
- Werving
- Leids Universitair Medisch Center
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Joris Rotmans
-
Nieuwegein, Nederland, 3435CM
- Werving
- Sint Antonius ziekenhuis Utrecht/Nieuwegein
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Gurbey Ocak
-
Nijmegen, Nederland, 6525 GA
- Werving
- Radboud Universitair Medisch Centrum
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Raphael Duivenvoorden
-
Utrecht, Nederland, 3584 CX
- Werving
- UMC Utrecht
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Sabine Meijvis
-
-
North Holland
-
Amsterdam, North Holland, Nederland, 1105 AZ
- Werving
- Amsterdam UMC - Locatie AMC (Academisch Medisch Centrum)
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Marc Hilhorst
-
-
-
-
-
Bergen, Noorwegen, 5021
- Werving
- Haukeland Universitetssjukehus
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Thomas Knoop
-
Grålum, Noorwegen, 1714
- Werving
- Sykehuset Ostfold
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Dumitrescu Ioana-Elena
-
Stavanger, Noorwegen
- Werving
- Stavanger Universitetssjukehus - Helse Stavanger HF
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Goransson Lasse
-
Trondheim, Noorwegen, 7030
- Werving
- Universitetssykehuset I Trondheim - St. Olavs Hospital - Nevroklinikken
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Yngvar Haaskjold
-
-
Akershus
-
Lorenskog, Akershus, Noorwegen, 1478
- Werving
- Akershus University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Bartlomiej Witczak
-
-
Vestfold
-
Tønsberg, Vestfold, Noorwegen
- Werving
- Sykehuset I Vestfold
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Kjellevold Stig Arne
-
-
-
-
-
Linz, Oostenrijk, 4040
- Werving
- Johannes Kepler Universitat Linz, Universitatsklinik fur Innere 2
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Alexander Moschen
-
Vienna, Oostenrijk, 1090
- Werving
- Medizinische Universitat Wien (Medical University of Vienna - Austria)
-
Hoofdonderzoeker:
- Rainer Oberbauer
-
Contact:
- Site Contact
-
-
-
-
-
Gmina Świecie, Polen, 86-100
- Werving
- Nowy Szpital Sp Zo.o
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Andrzej Brymora
-
Krakow, Polen, 31-559
- Werving
- SCM Sp. z o.o.
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Dariusz Aksamit
-
Lodz, Polen
- Werving
- Indywidualna Specjalistyczna Praktyka Lekarska
-
Hoofdonderzoeker:
- Michal Nowicki
-
Contact:
- Site Contact
-
Wroclaw, Polen, 50-981
- Werving
- 4th Military Clinical hospital /Polyclinic SP ZOZ
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Magdalena Krajewska
-
-
-
-
-
Singapore, Singapore
- Werving
- National University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Boon Wee Teo
-
Singapore, Singapore, 169608
- Werving
- Singapore General Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Jason Choo
-
Singapore, Singapore, 308433
- Werving
- Tan Tock Seng Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- See Cheng Yeo
-
-
-
-
-
Ljubljana, Slovenië, 1000
- Werving
- University Medical Centre Ljubljana
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Andreja Ales Rigler
-
Maribor, Slovenië
- Werving
- University Clinical Centre Maribor
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Sebastjan Bevc
-
-
-
-
-
Barcelona, Spanje, 8035
- Werving
- Hospital Universitari Vall d'Hebron
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Irene Agraz Pamplona
-
Barcelona, Spanje, 8003
- Werving
- Hospital del Mar
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Eva Rodriguez Garcia
-
Madrid, Spanje, 28027
- Werving
- Universidad de Navarra - Clinica Universidad de Navarra
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Jose Maria Mora Gutierrez
-
Madrid, Spanje, 28040
- Werving
- Fundacion Jimenez Diaz
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Roberto Scarpioni
-
Seville, Spanje, 41013
- Werving
- Hospital Universitario Virgen del Rocio - PPDS
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Manuel Lopez Mendoza
-
-
Barcelona
-
Badalona, Barcelona, Spanje, 8915
- Werving
- Hospital Universitari Germans Trias i Pujol
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Iara Karlla Da Silva Santos
-
-
Bizkaia
-
Barakaldo, Bizkaia, Spanje, 48903
- Werving
- Hospital Universitario de Cruces
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Laura Bueno Lopez
-
-
Navarre
-
Pamplona, Navarre, Spanje, 31008
- Werving
- Universidad de Navarra - Clinica Universidad de Navarra
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Jose Maria Mora Gutierrez
-
-
-
-
-
Kaohsiung City, Taiwan, 807
- Werving
- Kaohsiung Medical University - Chung-Ho Memorial Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Yi Wen Chiu
-
New Taipei City, Taiwan
- Werving
- Taipei Medical University Shuang Ho Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Mai-Szu Wu
-
Taichung, Taiwan, 40705
- Werving
- Taichung Veterans General Hospital
-
Hoofdonderzoeker:
- Ming-Ju Wu
-
Contact:
- Site Contact
-
Taichung, Taiwan
- Werving
- China Medical University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Ping-Chin Lai
-
Zhongzheng, Taiwan, 100
- Werving
- National Taiwan University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Jenq-Wen Huang
-
-
-
-
-
Olomouc, Tsjechië, 779 00
- Werving
- Fakultni nemocnice Olomouc
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Karel Krejci
-
Prague, Tsjechië
- Werving
- First Faculty of Medicine Charles University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Vladimir Tesar
-
-
Moravskoslezsk Kraj
-
Nový Jičín, Moravskoslezsk Kraj, Tsjechië, 741 01
- Werving
- Nemocnice AGEL Novy Jicin a.s
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Vaclava Honova
-
-
-
-
-
Kocaeli, Turkije (Türkiye)
- Werving
- Kocaeli Universitesi Tip Fakultesi Arastirma ve Uygulama Hastanesi
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Necmi Eren
-
-
Battalgazi
-
Malatya, Battalgazi, Turkije (Türkiye), 44280
- Werving
- Turgut Ozal Medical Center
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Ozkan Ulutas
-
-
Gaziantep
-
Şahinbey, Gaziantep, Turkije (Türkiye), 27310
- Werving
- Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Fatih Mehmet Erdur
-
-
Istanbul
-
Fatih, Istanbul, Turkije (Türkiye), 34098
- Werving
- Istanbul Universitesi Cerrahpasa Tip Fakultesi
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Nurhan Seyahi
-
-
Melikgazi
-
Kayseri, Melikgazi, Turkije (Türkiye), 38039
- Werving
- Erciyes University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Bulent Tokgoz
-
-
Onikisubat
-
Kahramanmaraş, Onikisubat, Turkije (Türkiye), 46040
- Werving
- Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Avsar Mah
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Orcum Altunoren
-
-
Selcuklu
-
Konya, Selcuklu, Turkije (Türkiye), 42280
- Werving
- Necmettin Erbakan University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Kultigin Turkmen
-
-
-
-
-
Canterbury, Verenigd Koninkrijk, CT1 3PA
- Werving
- Kent & Canterbury Hospital, Canterbury
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Tharindra Somasinghe
-
Hull, Verenigd Koninkrijk
- Werving
- Hull University Teaching Hospitals NHS Trust
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Sunil Bhandari
-
Leicester, Verenigd Koninkrijk
- Werving
- Leicester General Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Chee Kay Cheung
-
London, Verenigd Koninkrijk, WC2R 2LS
- Werving
- King's College Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Sapna Shah
-
London, Verenigd Koninkrijk, SW17 0QT
- Werving
- St George's University Hospitals NHS Foundation Trust
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Richard Hull
-
Nottingham, Verenigd Koninkrijk
- Werving
- Nottingham University Hospitals NHS Trust - City Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Matthew Hall
-
Preston, Verenigd Koninkrijk, PR29HT
- Werving
- Lancashire Teaching Hospital NHS Foundation Trust
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Arvind Ponnusamy
-
Sheffield, Verenigd Koninkrijk
- Werving
- Northern General Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Arif Khwaja
-
-
Greater London
-
London, Greater London, Verenigd Koninkrijk, SE1 9RT
- Werving
- Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Dimitrios-Anestis Moutzouris
-
-
United Kingdom of Great Britain and Northern Ireland
-
Birmingham, United Kingdom of Great Britain and Northern Ireland, Verenigd Koninkrijk
- Werving
- Birmingham Heartlands Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Bamidele Tokunbo Ajayi
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233-2110
- Werving
- UAB Nephrology Research Clinic at Paula Building
-
Hoofdonderzoeker:
- Dana Rizk
-
Contact:
- Site Contact
-
Montgomery, Alabama, Verenigde Staten, 36117
- Werving
- DCR Montgomery
-
Hoofdonderzoeker:
- Vinayak Ramanath
-
Contact:
- Site Contact
-
-
Arizona
-
Surprise, Arizona, Verenigde Staten, 85374
- Werving
- Panoramic Health - Southwest Kidney Institute, PLC
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Minesh Rajpal
-
-
California
-
Fremont, California, Verenigde Staten, 94538
- Werving
- Panoramic Health - West Coast Kidney Institute (Fremont)
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Varun Chawla
-
Los Angeles, California, Verenigde Staten, 90022
- Werving
- Academic Medical Research Institute
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Mohammed El-Shahwy
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- UCLA University of California Los Angeles
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Anjay Rastogi
-
Orange, California, Verenigde Staten, 92868-3201
- Werving
- University of California Irvine
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Ramy Hanna
-
San Francisco, California, Verenigde Staten, 94118
- Werving
- Kaiser Permanente San Francisco Medical Center
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Ali Poyan-Mehr
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32250
- Werving
- Panoramic Health - Florida Kidney Physicians, LLC (Jacksonville)
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Prasanth Krish
-
Lauderdale Lakes, Florida, Verenigde Staten, 33313-1607
- Werving
- South Florida Research Institute
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Edouard Martin
-
Melbourne, Florida, Verenigde Staten, 32901
- Werving
- Panoramic Health - Florida Kidney Physicians, LLC (Melbourne)
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Claus Peter Spies
-
Miami, Florida, Verenigde Staten, 33127
- Werving
- Bioresearch Partners
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Jose Miguel Cardona-Guzman
-
Miami, Florida, Verenigde Staten, 33176
- Werving
- Total Health and Research Center (THRC)
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Jeffrey Maldonado
-
Orlando, Florida, Verenigde Staten, 32806
- Werving
- CTR Oakwater, LLC
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Arvind Madan
-
Pembroke Pines, Florida, Verenigde Staten, 33029
- Werving
- Bioresearch Partners
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Max Benjamin
-
Riverview, Florida, Verenigde Staten, 33578
- Werving
- Panoramic Health - Florida Kidney Physicians, LLC (Tampa)
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Amit Augustine Johnsingh
-
Sanford, Florida, Verenigde Staten, 32771
- Werving
- Infigo Clinical Research LLC
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Sayed Husain
-
-
Georgia
-
Columbus, Georgia, Verenigde Staten, 31904
- Werving
- DCR Columbus
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Tamorie Smith
-
East Point, Georgia, Verenigde Staten, 30344
- Werving
- Panoramic Health - Southeast Kidney Associates
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Charmaine Ifeoma Emelife
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83706
- Werving
- CARE Institute - Boise Kidney
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Arnold Silva
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Northwestern University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Yonatan Peleg
-
Rockford, Illinois, Verenigde Staten, 61107
- Werving
- Panoramic Health - RNA of Rockford, LLC dba Rockford Nephrology Associates
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Syed Mustafa Ahmed
-
-
Louisiana
-
Shreveport, Louisiana, Verenigde Staten, 71101
- Werving
- Northwest Louisiana Nephrology
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Marwan Kaskas
-
-
Michigan
-
Lansing, Michigan, Verenigde Staten, 48911
- Werving
- Ingham Nephrology & Hypertension, P.C.
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Brian Cousino
-
Pontiac, Michigan, Verenigde Staten, 48341
- Werving
- Elixia MKC
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Fahd Al-Saghir
-
Saint Joseph, Michigan, Verenigde Staten, 49085
- Werving
- Panoramic Health - Lake Michigan Nephrology, PLC
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Oliver Chambers Songlingco
-
-
Minnesota
-
Edina, Minnesota, Verenigde Staten, 55435
- Werving
- DCR Edina
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Shannon Doyle
-
-
Missouri
-
City of Saint Peters, Missouri, Verenigde Staten, 63376
- Werving
- Elixia MNA
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Gary Singer
-
Kansas City, Missouri, Verenigde Staten, 64111
- Werving
- Clinical Research Consultants a JCCT Company
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Ahmed Awad
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87109
- Werving
- Renal Medicine Associates - Frenova F1
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Jayant Kumar
-
-
North Carolina
-
Winston-Salem, North Carolina, Verenigde Staten, 27103
- Werving
- Brookview Hills Research Associates, LLC
-
Hoofdonderzoeker:
- Nicholas McLean
-
Contact:
- Site Contact
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45212
- Werving
- Panoramic Health - Kidney and Hypertension Center
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- James Davis
-
-
Pennsylvania
-
Media, Pennsylvania, Verenigde Staten, 19063
- Werving
- Panoramic Health - Clinical Renal Associates, Ltd.
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Nathan Okechukwu
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Werving
- Thomas Jefferson University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Charlene Deng
-
-
Rhode Island
-
East Providence, Rhode Island, Verenigde Staten, 02914
- Werving
- Panoramic Health - Nephrology Associates, Inc.
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Larissa Kruger Gomes
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75230
- Werving
- Dallas Renal Group
-
Hoofdonderzoeker:
- Irfan Agha
-
Contact:
- Site Contact
-
El Paso, Texas, Verenigde Staten, 79902
- Werving
- DCR - El Paso
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Simon Rodriguez
-
Houston, Texas, Verenigde Staten, 77054
- Werving
- Provecta Research Network
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Sreedhar Mandayam
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Houston Methodist Research Institute - Department of Medicine
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Peter Nguyen
-
Katy, Texas, Verenigde Staten, 77450
- Werving
- Nephrology Associates of Houston PLLC
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Syed Hussain
-
San Antonio, Texas, Verenigde Staten, 78215
- Werving
- Sun Research Institute
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Reyes Leonel
-
San Antonio, Texas, Verenigde Staten, 78251
- Werving
- DCR San Antonio
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Tahira Alves
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84115
- Werving
- Utah Kidney Research Institute
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Sanjiv Anand
-
-
Virginia
-
Arlington, Virginia, Verenigde Staten, 22205
- Werving
- Panoramic Health - Virginia Nephrology Group
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Renuka Sothinathan
-
-
West Virginia
-
Morgantown, West Virginia, Verenigde Staten, 26506
- Werving
- West Virginia University
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Bethany Pellegrino
-
-
-
-
-
Seoul, Zuid -Korea, 3722
- Werving
- Severance Hospital, Yonsei University Health System
-
Hoofdonderzoeker:
- Seung Hyeok Han
-
Contact:
- Site Contact
-
Seoul, Zuid -Korea, 3080
- Werving
- Seoul National University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Dong Ki Kim
-
Seoul, Zuid -Korea, 7061
- Werving
- Seoul National University Boramae Medical Center
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Jung Pyo Lee
-
-
Gyeonggi-do
-
Yongin-si, Gyeonggi-do, Zuid -Korea, 16995
- Werving
- Yongin Severance Hospital, Yonsei University Health System
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Young Su Joo
-
-
Gyeonggido
-
Suwon, Gyeonggido, Zuid -Korea, 16499
- Werving
- Ajou University Hospital-Primary Research Location
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Inwhee Park
-
-
Seongnam
-
Seongnam-si, Seongnam, Zuid -Korea, 13620
- Werving
- Seoul National University Bundang Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Ho-Jun Chin
-
-
-
-
-
Linköping, Zweden
- Werving
- Renal Medicine Linkoping University/ Linkoping University Hospital
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Annette Bruchfeld
-
-
-
-
-
Zurich, Zwitserland, 8091
- Werving
- University Hospital Zurich
-
Contact:
- Site Contact
-
Hoofdonderzoeker:
- Britta George
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
- Inclusion Criteria:
To be eligible to participate in this trial, participants must meet all the following criteria:
-
Either UPCR greater than or equal to (≥) 0.8 gram per gram (g/g) or urine protein excretion (UPE) ≥1 grams per day (g/day), calculated from at least one 24-hour urine collection during the screening period (or pre-screening, if applicable) (only applicable for the main trial).
-
eGFR greater than (>)30 milliliters per minute per 1.73 meter square (mL/min/1.73m^2) at screening based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (only applicable for the main trial).
-
No prior exposure to anti- cluster of differentiation 38 (CD38) therapy period (except for open-label cohort participants meeting Inclusion Criterion No. 10.a).
-
The participant is aged ≥ 18 years or the local legal age as applicable.
-
The participant (and the participant's legally acceptable representative, as applicable per local regulations or determination) has provided informed consent (that is, in writing, documented via a signed and dated informed consent form [ICF]) and any required privacy authorization before the initiation of any clinical trial procedures.
-
Diagnosis of primary immunoglobulin A nephropathy (IgAN) supported by a renal biopsy report that is dated more recently than 10 years before the signing of the informed consent for the clinical trial. The redacted report must be made available for review. A renal biopsy must be performed during screening for participants without a biopsy report within 10 years.
-
Participants must be on stable renin-angiotensin-aldosterone system (RAAS) inhibitor therapy with an angiotensin-converting enzyme inhibitor (ACE-I) and/or angiotensin receptor blocker (ARB) or endothelin receptor antagonist (ERA) or mineralocorticoid receptor antagonist (MRA) agent for at least 12 weeks before signing the ICF with dosing at the maximally tolerated or labeled dose as determined by the investigator, with the intent to continue stable dosing during the clinical trial. Those intolerant of RAAS inhibitor therapy are potentially eligible after consultation with the medical monitor. Intolerance is defined as a documented side effect causing discontinuation of the therapy.
-
Resting blood pressure less than or equal to (≤)150 millimeters of mercury (mmHg) systolic and ≤100 mmHg diastolic.
-
Female participants of childbearing potential who are not pregnant during screening (confirmed by negative serum human chorionic gonadotropin [hCG]) and on Visit 1 before first dose of trial intervention (confirmed by negative urine pregnancy test).
-
Any one of the following (only applicable for participants in the open-label cohort):
-
Participants in Trial TAK-079-1006 who completed the Week 96 visit or the retreatment period with either UPCR >0.5 g/g or UPE >0.5 g/d calculated from a 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR >30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.
-
UPCR <0.8 g/g and UPE ≥0.75 and <1.0 g/day, by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR > 30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.
-
UPCR ≥ 0.8 g/g or UPE ≥ 1.0 g/d by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR ≥25 and ≤30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.
- Exclusion Criteria:
-
A participant who meets any of the following criteria will be excluded from participation in this trial:
-
Kidney biopsy exhibiting significant concomitant renal disease other than IgAN (for example, diabetic nephropathy, lupus nephritis, minimal change disease).
-
Secondary IgAN (such as with significant liver disease, inflammatory bowel disease, and seronegative spondyloarthropathies), and immunoglobulin A (IgA) vasculitis.
-
Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months before the signing of the ICF).
-
Diagnosis of nephrotic syndrome defined as 24-hour proteinuria >3.5 g/day and hypoalbuminemia (<3.0 grams per deciliter [g/dL]) with or without peripheral edema.
-
Renal or other organ transplantation prior to or expected during the clinical trial.
-
Treatment with oral immunosuppressive agents (including cyclophosphamide, mycophenolate mofetil, cyclosporine, azathioprine, calcineurin inhibitors) or biologic therapy for immunomodulation (including immunomodulatory monoclonal or polyclonal antibodies) within 6 months (both B-cell and non-B-cell directed agents) before signing of the ICF.
-
If the participant has received anti-CD20 treatment, the participant is excluded if either of the following apply:
- The last dose was received within 6 months before the signing of the ICF.
- The last dose was received between 6 and 12 months before the signing of the ICF and the participant has a CD19+ count below the lower limit of normal.
Note: Participants who have received the last dose of anti-CD20 treatment >12 months before the signing of the ICF are not excluded from clinical trial participation based on this criterion and are not required to undergo CD19+ testing.
-
Within 4 months of the screening visit, use of either a) systemic corticosteroids at an average dose of 40 milligrams (mg) prednisone equivalent or higher for more than 14 days or b) oral budesonide delayed release capsules.
-
The participant has received a live or live-attenuated vaccine within 4 weeks before signing the ICF or has any live or live-attenuated vaccine planned during the clinical trial.
-
Participation in any other investigational drug trial (including vaccine trial) with receipt of at least 1 dose of investigational drug, or has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Visit 1.
-
The participant has active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
-
The participant has had any of the following types of infections within the specified timeframes where applicable:
- Active bacterial, viral, or fungal infection (except for the common cold and onychomycosis), or any other serious infection within 2 weeks of signing the ICF. Any anti-infective course for infection must be completed at least 2 weeks before Visit 1.
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) infection within 4 weeks of signing the ICF.
- Opportunistic infection or treatment for an opportunistic infection less than or equal to (≤)12 weeks before signing the ICF.
- Active tuberculosis (TB), any history of prior active TB, or any signs or symptoms of active TB infection (including but not limited to chronic fever, chronic productive cough, night sweats, weight loss, or malnutrition) as judged by the investigator.
- For participants in European Union (EU) member states, positive or 2 indeterminant QuantiFERON results, unless there is documentation of prior complete treatment for latent TB, or participant has initiated prophylaxis based on local guidelines and in consultation with a pulmonology or infectious disease specialist prior to the first administration of IMP.
-
In the opinion of the investigator, the participant is currently experiencing any medical condition that might interfere with participation in the trial (for example, significant ocular, cardiovascular, pulmonary, hematologic, gastrointestinal, endocrinologic, hepatic, renal, neurologic, malignancy, infectious disease, immunodeficiency, or alcohol and drug abuse), that poses an added risk for the participant or could confound the assessment of trial results.
-
In the opinion of the investigator, the participant has a serious medical or psychiatric illness that could potentially interfere with the completion of treatment.
-
The participant has a history of major surgery within 3 months before screening (or longer, at the discretion of the investigator); or, either has a planned tonsillectomy or underwent a tonsillectomy within 6 months before screening.
Note: Major surgery typically requires at least 1 night in the hospital.
-
History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for adequately treated non-melanoma skin cancer, superficial bladder cancer, and curatively treated cervical carcinoma-in-situ.
-
The participant has a history of a severe allergic or anaphylactic reaction to recombinant proteins or excipients used in the mezagitamab or placebo formulation.
-
The participant has (1) been diagnosed with or has suspected chronic obstructive pulmonary disease (COPD) or asthma and (2) has a prebronchodilatory forced expiratory volume in 1 second (FEV1) <50% of predicted normal at screening.
-
The participant is capable of breastfeeding but does not agree to forego breastfeeding from first dose of investigational medicinal product (IMP) through 30 days after the last dose of IMP.
-
The participant is an individual with potential for pregnancy but does not agree to use at least 1 form of highly effective contraception and 1 barrier method of contraception (preferably male condom) when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.
-
The participant is a sexually active, non-sterilized individual who produces sperm but does not agree to use a barrier method (preferably male condom) combined with at least 1 form of highly effective contraception for any partner(s) with potential for pregnancy when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.
-
In the investigator's opinion, the participant (and the participant's legally acceptable representative, if applicable per local regulations or determination) is unwilling and/or unable to understand and fully comply with clinical trial procedures and requirements (including digital tools and applications).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Mezagitamab
Participants will receive mezagitamab injections, subcutaneously (SC), for approximately 22 weeks. |
Mezagitamab injections administered SC.
Andere namen:
|
|
Placebo-vergelijker: Placebo
Participants will receive mezagitamab-matching placebo injections, SC for approximately 22 weeks. |
Mezagitamab-matching placebo injections administered SC. |
|
Experimenteel: Open-label Mezagitamab
Participants will receive mezagitamab injections, SC for approximately 22 weeks. |
Mezagitamab injections administered SC.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline in Proteinuria at Week 36
Tijdsspanne: From Baseline to Week 36
|
Proteinuria will be assessed by urine protein to creatinine ratio (UPCR) calculated from a 24-hour urine collection. |
From Baseline to Week 36
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Verandering van de basislijn in geschatte glomerulaire filtratiesnelheid (EGFR) in respectievelijk week 52 en 104
Tijdsspanne: Van baseline tot weken 52 en 104
|
Van baseline tot weken 52 en 104
|
|
|
Time From Baseline to the First Occurrence of Sustained Decline in eGFR of ≥30 Percent (%) From Baseline Over at Least 4 Weeks
Tijdsspanne: From Baseline to Week 104
|
From Baseline to Week 104
|
|
|
Percentage of Participants Who Achieve ≥30% Reduction From Baseline in Proteinuria at Week 104
Tijdsspanne: From Baseline to Week 104
|
From Baseline to Week 104
|
|
|
The Rate of Change in eGFR From Baseline at Week 104
Tijdsspanne: From Baseline to Week 104
|
The rate of change in eGFR from baseline is measured as eGFR total slope. |
From Baseline to Week 104
|
|
Time from Baseline to the First Occurrence of Any of the Pre-specified Kidney Failure Composite Assessment Criteria
Tijdsspanne: From Baseline to Week 104
|
The pre-specified assessment criteria will include: sustained decline in eGFR of ≥30% from baseline over at least 4 weeks; sustained eGFR <15 mL/min/1.73 m^2 over at least 4 weeks; initiation of maintenance dialysis defined as dialysis performed for at least 4 weeks; receipt of kidney transplant; or death from kidney failure. Time from baseline to first occurrence of any of the above assessment criteria would be reported. |
From Baseline to Week 104
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Study Director, Takeda
Publicaties en nuttige links
Algemene publicaties
Nuttige links
- <p>Click here to ask Takeda's chatbot for comprehensive and easy-to-understand information about clinical trials - even across products and indications - in your local language.</p>
- <p>Click here for more information about this trial in easy-to-understand language, including a Plain Language Summary of the results if the trial has been completed.</p>
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TAK-079-3001
- 2025-520825-19-00 (Ctis)
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD-toegangscriteria voor delen
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .